Cytotoxicity of histocompatibility leukocyte Antigen-DR8-restricted CD4+ killer T cells against human autologous squamous cell carcinoma

Akihiro Miyazaki, Noriyuki Sato, Shuji Takahashi, Aya Sasaki, Gen Iku Kohama, Akira Yamaguchi, Atsuhito Yagihashi, Kokichi Kikuchi

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Although CD8+ killer T cells reacting against human autologous tumor cells have recently been studied in detail, little is known about the cytotoxic mechanism of CD4+ T cells against such tumor cells. In order to investigate this, we have established CD4+ cytotoxic T lymphocyte TcOSC-20 lines. TcOSC-20 showed selective cytotoxic activity against autologous OSC-20 cells, derived from a cancer of the tongue, in an HLA-DR-restricted fashion. HLA-DR8 (DRB1(*)08032) is the only DR molecule expressed on OSC-20 cells, and anti-DR8 monoclonal antibody could inhibit the cytotoxicity, suggesting that HLA-DRB1(*)08032 is the tumor rejection antigen-presenting molecule to TcOSC-20. The Fas ligand was expressed on TcOSC-20 lines, and its expression was induced upon mixed lymphocyte-tumor cell culture of autologous peripheral blood lymphocytes. Furthermore, the cytotoxicity of TcOSC-20 was inhibited by anti-Fas ligand antibody. These data imply that TcOSC-20 lines recognize the tumor antigenic peptide presented by HLA-DR8, and exert cytotoxicity against autologous tumor cells via a Fas-mediated cytotoxic pathway.

Original languageEnglish
Pages (from-to)191-197
Number of pages7
JournalJapanese Journal of Cancer Research
Issue number2
Publication statusPublished - 1997


  • Autologous tumor
  • Fas antigen
  • HLA-DR8
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cytotoxicity of histocompatibility leukocyte Antigen-DR8-restricted CD4<sup>+</sup> killer T cells against human autologous squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this